8-K: Savara's Molgramostim Achieves Positive Topline Results in Phase 3 aPAP Trial

Savara Inc. announced positive topline results from its Phase 3 IMPALA-2 clinical trial, demonstrating the efficacy and safety of molgramostim in treating autoimmune pulmonary alveolar proteinosis (aPAP).

Summary

• Savara Inc. has released positive topline results from the IMPALA-2 Phase 3 clinical trial for molgramostim, an inhaled treatment for autoimmune pulmonary alveolar proteinosis (aPAP).
• The trial met its primary endpoint, showing a statistically significant improvement in lung function (DLCO) at week 24 compared to placebo, with a mean change of 6.00 and a p-value of 0.0007.
• This improvement was sustained at week 48, a secondary endpoint, with a mean change of 6.90 and a p-value of 0.0008, indicating a durable effect.
• Molgramostim also showed clinical benefits in secondary endpoints, including the St. Georges Respiratory Questionnaire (SGRQ) Total Score, SGRQ Activity Component Score, and exercise capacity, with some reaching statistical or nominal significance.
• The treatment was well-tolerated, with a similar frequency of adverse events between the molgramostim and placebo groups, and only 2.5% of patients discontinuing due to adverse events unrelated to the trial drug.
• Savara plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2025.
• The trial involved 164 patients across 43 sites in 16 countries.

Sentiment

Score: 9

Explanation: The document presents very positive results from a Phase 3 trial, with strong efficacy and safety data, and a clear path to regulatory submission. The sentiment is highly positive due to the potential for molgramostim to become a first-in-class treatment for aPAP.

Positives

• The trial achieved its primary endpoint with statistically significant improvement in lung function.
• The treatment effect was durable, with sustained improvement at week 48.
• Molgramostim showed clinical benefits in multiple secondary endpoints related to quality of life and exercise capacity.
• The treatment was well-tolerated with a low discontinuation rate due to adverse events.
• The company plans to submit a BLA to the FDA in the first half of 2025.
• Molgramostim has received multiple designations from regulatory agencies, including Orphan Drug, Fast Track, and Breakthrough Therapy designations from the FDA.

Negatives

• Some secondary endpoints, while showing improvement, only reached nominal significance.
• COVID-19 was more frequently reported in the molgramostim group than the placebo group, although this was not considered a treatment related adverse event.

Risks

• The analysis of the full data set from the IMPALA-2 clinical trial could reveal observations not seen in the topline results.
• There are risks associated with the ability to successfully develop, obtain regulatory approval for, and commercialize molgramostim.
• Widespread health concerns and geopolitical conditions could impact the business and operations.
• The company's ability to project future cash utilization and raise additional capital is a risk.

Future Outlook

Savara plans to complete the submission of a Biologics License Application with the U.S. Food and Drug Administration (FDA) for molgramostim for the treatment of aPAP in the first half of 2025 and anticipates submitting the full data from IMPALA-2 for presentation at a scientific conference later this year.

Management Comments

• Bruce Trapnell, M.D., stated that the evidence now clearly demonstrates molgramostim has the potential to be a safe and efficacious treatment option for aPAP patients.
• Matt Pauls, Chair and CEO of Savara, said that the IMPALA-2 results exceeded expectations and validated the hypothesis that molgramostim provides clear, durable improvement in gas exchange and clinical benefits.

Industry Context

This announcement is significant in the rare respiratory disease space, as there is a high unmet need for effective treatments for aPAP. The positive results from the IMPALA-2 trial position molgramostim as a potential first-in-class therapy for this condition, potentially impacting the treatment landscape for aPAP.

Comparison to Industry Standards

• The IMPALA-2 trial results are compared to placebo, which is standard for clinical trials.
• The primary endpoint of DLCO improvement is a common measure in respiratory disease trials.
• The use of the SGRQ is a recognized method for assessing patient-reported outcomes in respiratory conditions.
• The trial's design, including the 48-week double-blind period and the option for a 96-week open-label extension, is consistent with industry standards for evaluating long-term efficacy and safety.
• There are no direct comparible companies or projects mentioned in the document, however, the results are compared to the placebo group which is standard practice.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results.
• Patients with aPAP may benefit from a new treatment option.
• Clinicians will have a new potential therapy to offer their patients.
• Employees of Savara may experience increased job security and opportunities.

Next Steps

• Savara plans to complete the submission of a Biologics License Application (BLA) to the FDA in the first half of 2025.
• The company anticipates submitting the full data from IMPALA-2 for presentation at a scientific conference later this year.
• Patients may continue in a 96-week open-label period following the 48-week double-blind treatment period.

Key Dates

Keywords

molgramostim, aPAP, pulmonary alveolar proteinosis, IMPALA-2, clinical trial, respiratory disease, lung function, DLCO, SGRQ, FDA, Biologics License Application, GM-CSF